Drägerwerk reports 5.3 percent sales growth. Drägerwerk stock sits 16.99 percent below its high

Published on 10/29/2026 at 09:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

EBIT reached EUR 111.80 million in nine months. Drägerwerk stock costs EUR 104.10 on October 29, 2026, below the EUR 104.60 Xetra close.

Nine-month results and outlook

Drägerwerk published its first nine-month 2026 results on October 29, 2026.
Currency-adjusted sales increased 5.3 percent to EUR 2,453.9 million in the first nine months of 2026.
Drägerwerk stock trades at EUR 104.10 at 9:44 a.m. CET at Lang & Schwarz on October 29, 2026, 0.48 percent below the Xetra close of October 28, 2026.
The company retained its 2026 sales-growth outlook of 2.0 to 6.0 percent and EBIT-margin outlook of 6.0 to 8.0 percent.

Drägerwerk, DE0005550636, Illustration mit AI erstellt.

Drägerwerk (ISIN DE0005550636) increased currency-adjusted sales 5.3 percent to EUR 2,453.9 million in the first nine months of 2026, while EBIT reached EUR 111.8 million. The company released the figures on October 29, 2026, in an announcement verified by Deutsche Boerse. The release identified customs refunds as a one-off contribution to earnings.

Sales growth reaches both divisions

The result was broader than the headline figures suggest. Medical Technology sales rose 4.4 percent on a currency-adjusted basis to EUR 1,367.0 million in the first nine months of 2026, while Safety Technology sales increased 6.5 percent to EUR 1,087.0 million, according to Deutsche Boerse. Safety order intake increased 13.1 percent to EUR 1,242.8 million, contrasting with a 3.5 percent decline in medical order intake to EUR 1,430.7 million.

EBIT included EUR 27.9 million from customs refunds, including EUR 20.1 million related to the third quarter. The EBIT margin therefore improved to 4.6 percent from 3.3 percent in the first nine months of 2025, but the one-off effect remains material for assessing underlying profitability.

What does the guidance mean for margins?

Drägerwerk retained its currency-adjusted 2026 sales-growth outlook of 2.0 to 6.0 percent and its EBIT-margin range of 6.0 to 8.0 percent. The company also reported third-quarter order intake of EUR 926.2 million, up 7.0 percent on a currency-adjusted basis, while third-quarter EBIT was EUR 48.0 million versus EUR 56.7 million a year earlier.

The figures leave investors with a clear test: stronger safety demand must translate into recurring operating profit after the customs refunds fade. That makes the margin path more important than sales growth alone.

Stock stays below its yearly high

Drägerwerk stock was trading at EUR 104.10 at Lang & Schwarz on October 29, 2026, at 9:44 a.m. CET, down 0.48 percent versus the Xetra close of October 28, 2026, at EUR 104.60. The 52-week high is EUR 125.40, placing the current quote 16.99 percent below that level.

The further course of trading is shown by the continuously updated real-time quote of Drägerwerk stock.